Property | Value |
?:abstract
|
-
BACKGROUND: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 ... »more»
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
|
?:doi
|
-
10.1186/s12879-020-05701-4
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/5b3748e977913a37b3895369d0a5d705cbb9fe82.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7755065.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
is
?:relation_isRelatedTo_publication
of
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Effects of Tocilizumab in COVID-19 patients: a cohort study
|
?:type
|
|
?:year
|
|